Compare AbbVie Inc (ABBV) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Shell PLC — how do they compare? AbbVie Inc trades at $248.55 (market cap $441.94B), while Shell PLC trades at $90.25 (market cap $250.44B). The key difference: AbbVie Inc is the larger of the two by market cap, and Shell PLC pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| ABBV | SHEL | |
|---|---|---|
Market Cap | $441.94B | $250.44B |
Sector | Health | Energy |
52-Week High | $263.58 | $94.15 |
52-Week Low | $197.38 | $70.31 |
Enterprise Value | $506.19B | $292.14B |
Dividend Yield | 2.77% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Shell (SHEL) trades at $89.95, up 1.64% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The stock shows attractive valuation with a P/E of 10.01 and P/S of 0.88, supported by robust cash flow and a 14.35% ROE. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments in renewables.
Outlook is positive with a $103.60 consensus price target and 69% buy ratings, though risks include commodity volatility and regulatory pressures. Earnings growth and debt reduction provide upside, while geopolitical tensions and energy transition uncertainties remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
